EASTBOURNE registry analysis shows “very good” safety and efficacy of novel sirolimus-coated balloon

Bernardo Cortese (Milan, Italy) talks to BLearning about the EASTBOURNE registry, which he states is the “largest registry ever on a drug-coated balloon (DCB) for coronary applications”.

Cortese presented the interim results in a late-breaking session at EuroPCR 2019 (21–24 May, Paris, France), which looked at the “feasibility, safety and the long-term efficacy” of a novel sirolimus-coated balloon.

The interim analysis, of 650 patients at one-month follow-up, found “very low clinical events, no safety signals and very good efficacy”. Additionally, in a limited population of 207 patients with 12-month follow-up, the primary endpoint results were “also low” and there was a 2.4 rate of target lesion revascularisation – leading Cortese to remark that the preliminary signals are “very good with this device”.

These results, notes Cortese, come at “a very important time for DCBs” because there are “some signals of lower safety at the long-term for peripheral DCB and paclitaxel-eluting devices”.

Cortese, Bernardo

Dr Bernardo Cortese is a consultant interventional cardiologist, and chief of research innovation and development at the Cardiac Department at the Clinica San Carlo, in Milan, Italy. He was one of the first experts on the use of drug eluting balloon technology, and has been primary investigator for many trials, including most recently TRANSFORM II (sirolimus-coated balloon versus everolimus eluting stent in small vessels), TRANSFORM I (sirolimus-coated balloon versus paclitaxel drug coated balloon in small vessels), and the ROCK study (optical coherence tomography guidance during left main percutaneous coronary intervention)

Add comment

Editor’s Cardiovascular Pick

    Subscribe to receive the very best in medical videos

    /* ]]> */